CRISPR 시장 규모, 점유율, 성장, 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of CRISPR Market

The global CRISPR market was valued at USD 3.05 billion in 2025 and is projected to grow from USD 3.41 billion in 2026 to USD 10.81 billion by 2034, registering a strong CAGR of 15.49% during the forecast period. The rapid adoption of gene-editing technologies across biotechnology, pharmaceutical research, drug discovery, and therapeutic development is significantly driving market expansion. North America dominated the global CRISPR market with a 43.93% share in 2025, supported by strong biotechnology infrastructure, extensive research funding, and the presence of leading market participants.

CRISPR technology has become one of the most transformative tools in genome engineering, enabling highly precise gene editing, functional genomics studies, cell engineering, and translational research. The increasing demand for advanced gene-editing workflows, coupled with growing investments in precision medicine and rare disease research, continues to accelerate market growth. Major companies such as Thermo Fisher Scientific, Danaher Corporation (IDT and Aldevron), Merck KGaA, GenScript, Synthego, and Takara Bio are expanding their CRISPR portfolios through investments in reagents, nucleases, bioinformatics tools, and therapeutic development platforms.

Market Trends

A major trend shaping the CRISPR market is the advancement of genome engineering technologies and the development of CRISPR-based therapies. Researchers are increasingly focusing on improving editing accuracy, reducing off-target effects, and accelerating clinical translation. The emergence of personalized gene-editing therapies and next-generation CRISPR platforms is creating significant opportunities for technology providers and biotechnology companies.

Market Drivers

Increasing Adoption of Gene Editing Technologies in Biotechnology

The growing use of gene-editing tools in biotechnology and pharmaceutical research is a key factor driving CRISPR market growth. Biotechnology companies are increasingly utilizing CRISPR for target identification, functional genomics, cell engineering, and therapeutic development. The technology's ability to accelerate research timelines and improve precision has increased demand for guide RNAs, nucleases, delivery systems, and analytical services. Furthermore, expanding applications in personalized medicine and rare disease treatment continue to strengthen market demand.

Market Restraints

Ethical Concerns Related to Gene Editing

Ethical issues surrounding human genome editing remain a significant restraint for market expansion. Concerns regarding germline modification, embryo editing, consent, and potential misuse of genetic technologies have led to increased regulatory scrutiny. These challenges may delay commercialization of certain applications and increase compliance requirements for industry participants.

Market Opportunities

Rising Investments in Genetic Research

Increasing investments in genetic and genomic research are creating substantial opportunities for the CRISPR market. Funding from governments, research institutions, biotechnology firms, and private investors is supporting the development of advanced genome-editing technologies. Higher investments are enabling organizations to expand research capabilities, accelerate preclinical studies, and move promising therapies toward clinical development.

Market Challenges

High Research and Development Costs

The development of CRISPR-based therapies requires significant investments in research, manufacturing, regulatory approvals, and clinical trials. High R&D expenses create barriers for smaller companies and startups, often limiting the number of projects that can advance through the development pipeline. Maintaining long-term funding remains a major challenge across the industry.

Segmentation Analysis

By Offering

The products segment dominated the market in 2025 due to the recurring demand for kits, reagents, CRISPR libraries, nucleases, vectors, and delivery tools used in research and therapeutic workflows. Continuous innovation in gene-editing reagents is supporting segment growth.

The software and bioinformatics tools segment is expected to witness the fastest growth during the forecast period, driven by increasing demand for off-target analysis, genomic data interpretation, and workflow optimization.

By Technology

The CRISPR-Cas9 segment held the largest market share in 2025 due to its widespread adoption in gene-editing research and therapeutic applications. Its high editing efficiency and extensive commercial availability continue to support market leadership.

The CRISPR-Cas13 segment is expected to experience strong growth owing to its emerging applications in RNA editing and molecular diagnostics.

By Application

The basic and translational research segment dominated the market in 2025. Academic institutions, research laboratories, and biotechnology companies extensively utilize CRISPR for gene function studies, disease modeling, and pathway analysis.

The therapeutic development segment is anticipated to grow rapidly as more CRISPR-based therapies enter preclinical and clinical development stages.

By End User

The pharmaceutical and biotechnology companies segment accounted for the largest market share in 2025. These organizations are making significant investments in CRISPR-based drug discovery, gene therapies, and precision medicine programs.

The CROs and CDMOs segment is projected to witness substantial growth due to increasing outsourcing of gene-editing research and manufacturing activities.

Regional Outlook

North America

North America remained the largest regional market, reaching USD 1.34 billion in 2025. Strong biotechnology infrastructure, advanced research capabilities, and substantial funding for genomic medicine support regional growth. The U.S. continues to be the leading contributor to regional revenues.

Europe

Europe is expected to experience robust growth during the forecast period, supported by expanding genetic research programs, public-private collaborations, and growing adoption of CRISPR technologies in drug development and translational medicine.

Asia Pacific

Asia Pacific is projected to be the fastest-growing regional market. Rising biotechnology investments, expanding genomics research, and improving healthcare infrastructure in countries such as China, Japan, India, and South Korea are driving market expansion.

Latin America and Middle East & Africa

These regions are witnessing gradual growth due to increasing investments in life sciences research, improving biotechnology capabilities, and rising awareness of advanced genomic technologies.

Competitive Landscape

The global CRISPR market is moderately fragmented, with leading companies focusing on product innovation, strategic collaborations, acquisitions, and expansion of translational research capabilities. Major players include Thermo Fisher Scientific Inc., Danaher Corporation (IDT and Aldevron), Merck KGaA, GenScript, Synthego, Takara Bio Inc., OriGene Technologies, Twist Bioscience, Revvity Discovery Limited, and BPS Bioscience.

Recent developments include the launch of advanced CRISPR reagents, strategic partnerships for therapeutic development, AI-enhanced gene-editing platforms, and investments in genome engineering technologies aimed at improving precision and accelerating clinical translation.

Conclusion

The CRISPR market is entering a phase of rapid expansion, driven by growing adoption of gene-editing technologies, rising investments in genetic research, and increasing development of CRISPR-based therapeutics. Valued at USD 3.05 billion in 2025, the market is expected to reach USD 10.81 billion by 2034, reflecting the transformative role of genome engineering in biotechnology and precision medicine. While ethical concerns and high development costs remain challenges, continued innovation, expanding clinical applications, and strong industry investment are expected to create significant growth opportunities throughout the forecast period.

Segmentation By Offering, Technology, Application, End User, and Region

By Offering * Products

• Instruments
• CRISPR Libraries
• Enzymes/Cas Proteins/Nucleases
• Vectors/Plasmids/Delivery Tools
• Others
• Software & Bioinformatics Tools
• Services

By Technology * CRISPR-Cas9

• CRISPR-Cas12
• CRISPR-Cas13
• Others

By Application * Basic & Translational Research

• Drug Discovery & Target Identification
• Preclinical Model Development
• Therapeutic Development
• Diagnostics
• Others

By End User * Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes
• CROs/CDMOs
• Diagnostic Laboratories
• Others

By Region * North America (By Offering, Technology, Application, End User, and Country)

• U.S.
• Canada
• Europe (By Offering, Technology, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Offering, Technology, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Offering, Technology, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Offering, Technology, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends
• 3.5. Market Challenges

4. Key Insights

• 4.1. Technological Advancements in CRISPR Technology
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global CRISPR Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Offering
  • 5.1.1. Products
    • 5.1.1.1. Kits & Reagents
    • 5.1.1.2. CRISPR Libraries
    • 5.1.1.3. Enzymes/Cas Proteins/Nucleases
    • 5.1.1.4. Vectors/Plasmids/Delivery Tools
    • 5.1.1.5. Others
  • 5.1.2. Software & Bioinformatics Tools
  • 5.1.3. Services
• 5.2. Market Analysis, Insights and Forecast - By Technology
  • 5.2.1. CRISPR-Cas9
  • 5.2.2. CRISPR-Cas12
  • 5.2.3. CRISPR-Cas13
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Basic & Translational Research
  • 5.3.2. Drug Discovery & Target Identification
  • 5.3.3. Preclinical Model Development
  • 5.3.4. Therapeutic Development
  • 5.3.5. Diagnostics
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Pharmaceutical & Biotechnology Companies
  • 5.4.2. Academic & Research Institutes
  • 5.4.3. CROs/CDMOs
  • 5.4.4. Diagnostic Laboratories
  • 5.4.5. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America CRISPR Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Offering
  • 6.1.1. Products
    • 6.1.1.1. Kits & Reagents
    • 6.1.1.2. CRISPR Libraries
    • 6.1.1.3. Enzymes/Cas Proteins/Nucleases
    • 6.1.1.4. Vectors/Plasmids/Delivery Tools
    • 6.1.1.5. Others
  • 6.1.2. Software & Bioinformatics Tools
  • 6.1.3. Services
• 6.2. Market Analysis, Insights and Forecast - By Technology
  • 6.2.1. CRISPR-Cas9
  • 6.2.2. CRISPR-Cas12
  • 6.2.3. CRISPR-Cas13
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Basic & Translational Research
  • 6.3.2. Drug Discovery & Target Identification
  • 6.3.3. Preclinical Model Development
  • 6.3.4. Therapeutic Development
  • 6.3.5. Diagnostics
  • 6.3.6. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Pharmaceutical & Biotechnology Companies
  • 6.4.2. Academic & Research Institutes
  • 6.4.3. CROs/CDMOs
  • 6.4.4. Diagnostic Laboratories
  • 6.4.5. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe CRISPR Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Offering
  • 7.1.1. Products
    • 7.1.1.1. Kits & Reagents
    • 7.1.1.2. CRISPR Libraries
    • 7.1.1.3. Enzymes/Cas Proteins/Nucleases
    • 7.1.1.4. Vectors/Plasmids/Delivery Tools
    • 7.1.1.5. Others
  • 7.1.2. Software & Bioinformatics Tools
  • 7.1.3. Services
• 7.2. Market Analysis, Insights and Forecast - By Technology
  • 7.2.1. CRISPR-Cas9
  • 7.2.2. CRISPR-Cas12
  • 7.2.3. CRISPR-Cas13
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Basic & Translational Research
  • 7.3.2. Drug Discovery & Target Identification
  • 7.3.3. Preclinical Model Development
  • 7.3.4. Therapeutic Development
  • 7.3.5. Diagnostics
  • 7.3.6. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Pharmaceutical & Biotechnology Companies
  • 7.4.2. Academic & Research Institutes
  • 7.4.3. CROs/CDMOs
  • 7.4.4. Diagnostic Laboratories
  • 7.4.5. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific CRISPR Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Offering
  • 8.1.1. Products
    • 8.1.1.1. Kits & Reagents
    • 8.1.1.2. CRISPR Libraries
    • 8.1.1.3. Enzymes/Cas Proteins/Nucleases
    • 8.1.1.4. Vectors/Plasmids/Delivery Tools
    • 8.1.1.5. Others
  • 8.1.2. Software & Bioinformatics Tools
  • 8.1.3. Services
• 8.2. Market Analysis, Insights and Forecast - By Technology
  • 8.2.1. CRISPR-Cas9
  • 8.2.2. CRISPR-Cas12
  • 8.2.3. CRISPR-Cas13
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Basic & Translational Research
  • 8.3.2. Drug Discovery & Target Identification
  • 8.3.3. Preclinical Model Development
  • 8.3.4. Therapeutic Development
  • 8.3.5. Diagnostics
  • 8.3.6. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Pharmaceutical & Biotechnology Companies
  • 8.4.2. Academic & Research Institutes
  • 8.4.3. CROs/CDMOs
  • 8.4.4. Diagnostic Laboratories
  • 8.4.5. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America CRISPR Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Offering
  • 9.1.1. Products
    • 9.1.1.1. Kits & Reagents
    • 9.1.1.2. CRISPR Libraries
    • 9.1.1.3. Enzymes/Cas Proteins/Nucleases
    • 9.1.1.4. Vectors/Plasmids/Delivery Tools
    • 9.1.1.5. Others
  • 9.1.2. Software & Bioinformatics Tools
  • 9.1.3. Services
• 9.2. Market Analysis, Insights and Forecast - By Technology
  • 9.2.1. CRISPR-Cas9
  • 9.2.2. CRISPR-Cas12
  • 9.2.3. CRISPR-Cas13
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Basic & Translational Research
  • 9.3.2. Drug Discovery & Target Identification
  • 9.3.3. Preclinical Model Development
  • 9.3.4. Therapeutic Development
  • 9.3.5. Diagnostics
  • 9.3.6. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Pharmaceutical & Biotechnology Companies
  • 9.4.2. Academic & Research Institutes
  • 9.4.3. CROs/CDMOs
  • 9.4.4. Diagnostic Laboratories
  • 9.4.5. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa CRISPR Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Offering
  • 10.1.1. Products
    • 10.1.1.1. Kits & Reagents
    • 10.1.1.2. CRISPR Libraries
    • 10.1.1.3. Enzymes/Cas Proteins/Nucleases
    • 10.1.1.4. Vectors/Plasmids/Delivery Tools
    • 10.1.1.5. Others
  • 10.1.2. Software & Bioinformatics Tools
  • 10.1.3. Services
• 10.2. Market Analysis, Insights and Forecast - By Technology
  • 10.2.1. CRISPR-Cas9
  • 10.2.2. CRISPR-Cas12
  • 10.2.3. CRISPR-Cas13
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Basic & Translational Research
  • 10.3.2. Drug Discovery & Target Identification
  • 10.3.3. Preclinical Model Development
  • 10.3.4. Therapeutic Development
  • 10.3.5. Diagnostics
  • 10.3.6. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Pharmaceutical & Biotechnology Companies
  • 10.4.2. Academic & Research Institutes
  • 10.4.3. CROs/CDMOs
  • 10.4.4. Diagnostic Laboratories
  • 10.4.5. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Revvity Discovery Limited
  • 11.2.2. GenScript
  • 11.2.3. Merck KGaA
  • 11.2.4. Thermo Fisher Scientific Inc.
  • 11.2.5. Danaher Corporation (Integrated DNA Technologies, Inc.)
  • 11.2.6. Synthego
  • 11.2.7. Takara Bio Inc.
  • 11.2.8. OriGene Technologies, Inc.
  • 11.2.9. Twist Biosciences
  • 11.2.10. BPS Bioscience, Inc.